
The Mohn Center for Precision Medicine in Diabetes (PRECISE-DIA) is seeking a full-time researcher (100%) for a 3-year position affiliated with the project “Beyond Type 1 Diabetes: Precision Medicine in HNF1B-MODY”, funded by Helse Vest for the period 2026–2028.
The project aims to functionally investigate the role of the transcription factor HNF-1B in diabetes. It is a collaboration between the Department of Pediatrics and Adolescent Medicine, Haukeland University Hospital, and the Faculty of Medicine, University of Bergen. The project is led by Professor and Senior Consultant Pål Rasmus Njølstad.
About the project
Diabetes and its complications are among the greatest global health challenges of the 21st century. One important subtype is Maturity-onset Diabetes of the Young (MODY), an autosomal dominant form of diabetes and a key example of precision medicine, which is often misdiagnosed as type 1 diabetes. Pathogenic sequence variants in the transcription factor gene HNF1B cause HNF1B-MODY, a condition that may also involve organ dysfunction, including pancreatic aplasia, kidney malformations, severe renal failure, genital malformations, and neuropsychiatric disease.
Haukeland University Hospital and the University of Bergen are internationally recognised for research into the clinical, genetic, and functional basis of monogenic diabetes. In this project, exome sequencing will be used to determine the prevalence of undiagnosed HNF1B-MODY in children and adults with presumed type 1 diabetes included in the Norwegian Childhood Diabetes Registry and the Norwegian Diabetes Registry for Adults.
Patients found to carry pathogenic variants will receive a precise molecular diagnosis, along with improved genetic counselling and treatment. They will also be invited to participate in a treatment study investigating whether insulin injections can be replaced by sulfonylurea tablets, as some patients with HNF1B-MODY respond to sulfonylureas.
Genetic data and protein function data will be integrated through multidimensional analyses and machine learning and related to clinical phenotype. This may improve prediction of diagnosis and treatment among patients with HNF1B-MODY. Functional studies of HNF1B variants will also be carried out in the world’s largest HNF1B-MODY cohort, contributing to a revision of the international diagnostic criteria for HNF1B-MODY. The project may include studies of interaction partners to the HNF-1B protein as well as biochemical and 3D-analysis of selected variants. Also, the candidate will be involved in a subproject aiming to make a high-throughput assay for investigating all theoretically possible missense variants in the HNF-1B protein (MAVE). The project is expected to have immediate impact on both diagnosis and treatment.
The position involves demanding and specialised technical and academic support functions related to research and teaching.
The successful candidate is expected to have substantial laboratory expertise in biochemical/ molecular biological methods. Advantages are experience with research on transcription factors or analyses of mutations in diabetes genes, including:
The position involves demanding and specialised technical and academic support functions related to research and teaching.
The successful candidate is expected to have substantial laboratory expertise in biochemical/ molecular biological methods. Advantages are experience with research on transcription factors or analyses of mutations in diabetes genes, including:
Applicants must have:
Experience from international collaboration is an advantage.
Personal suitability will be an important part of the overall assessment
The application must include:
Conditions attached to the position:
The following conditions apply to the Researcher position:
For Norwegian applicants, please apply via Webcruiter.
English‑speaking applicants may submit their application as a PDF to: pal.njolstad@uib.no